Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27

Entrada Therapeutics, Inc. (TRDA) recorded a narrower loss for the second quarter ended June 30, 2026, and highlighted various clinical updates. Company Profile Entrada is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics for genetic diseases using its proprietary Endosomal Escape Vehicle (EEV) platform.